Queen's University BladderNow it was not released in a PR or NR as of yet but on several slides on the new presenation there is talk about Bladder Cancer tests and specifically with Queen's University. Now researching the past Pharmagap and Queen's do have a history together with testing a previous incarnation of the drug and it does look like this Fall it will continue. Based on the presentation there is plans for a G "In vivoMTD and tumoralmodel study (Bladder, Queens U.)" What was also interesting is that on slide 12 of the presenation they talk about Clinical Trial Strategy and they talk about sub-Optimal treaments out now which they indicate Bladder Cancer as the one for their example. Since this will be a new round of testing it is likely the reason for a longer wait on Phase 1 application. They know based on the NCI test Prostate cancers cells are the most effective against the drug and also a bigger industry then ovarian or melenoma. The gamble could be, since they are likely ask to pay for the testing, see how it really works against bladder cells and go Phase 1 with that.
So what could this have to do with the PP and warrants well I am thinking they are going to use this funds right now to get the results for Bladder and gamble it will be as good as they think they should be and go phase 1 on that. Hopefully the company will release when they are begining testings instead of telling us the results after the fact. Need to build back interest and desire to own the stock.